Mekophar Chemical Pharmaceutical JSC

Mekophar Chemical Pharmaceutical JSC has a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative leverage position. The company's liquidity is characterized by a current ratio of 5.76, suggesting strong short-term liquidity. However, the company reported negative operating cash flow of -34,404,509,880 VND and free cash flow of -2,373,762,700 VND, indicating cash flow challenges.

Profitability metrics show a return on equity of -0.0059 and a return on assets of -0.0047, both negative, which is below the typical performance of the pharmaceutical industry. The company's operating income was -8,642,403,180 VND, and net income was -7,360,977,350 VND, reflecting a significant decline in profitability.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks.

The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The reported revenue of 224,578,071,700 VND is lower than the analyst estimate of 1,366,680,618,340 VND, suggesting potential underperformance. The company's capital expenditure of -6,984,988,370 VND indicates ongoing investment in infrastructure or operations.

Risk factors include low liquidity and the absence of immediate filing-based liquidity or dilution flags. The company's dilution potential is low, and no significant adjustments were applied to the valuation metrics. The company's recent financial performance and cash flow challenges may impact its ability to sustain operations and invest in growth.

Recent events, including filings and transcripts, do not indicate any significant developments that would alter the company's current financial position or strategic direction.

Net income surged 62.4% year-over-year to 40.8 billion VND, demonstrating strong recent profitability growth momentum.

Free cash flow increased 113.9% year-over-year to 66.3 billion VND, indicating robust cash generation capabilities.

The company maintains a zero debt-to-equity ratio, ranking above the 75th percentile within the pharmaceutical cohort.

Cash conversion of 4.67 is best-in-class compared to the pharmaceutical cohort median of 0.95.

Risk flags for dilution, liquidity, and credit are all assessed at low levels, suggesting minimal immediate financial risks.

Revenue declined with a negative 0.9% CAGR over four years, signaling a lack of top-line growth.

Return on invested capital is negative at -0.69%, suggesting the company fails to generate value on invested capital.

Revenue VND 207.86B, −9,5% YoY; Operating income +115,5% YoY.

• ▍Revenue VND 207.86B, −9,5% YoY
• ▍Operating income +115,5% YoY
• ▍Net income +112,0% YoY
• ▍Free cash flow +205,4% YoY
• ▍Net margin 0.8%

Revenue VND 938.95B, +3,6% YoY; Operating income −91,6% YoY.

• ▍Revenue VND 938.95B, +3,6% YoY
• ▍Operating income −91,6% YoY
• ▍Net income −89,5% YoY
• ▍Free cash flow −86,2% YoY
• ▍Net margin 0.5%